MTOR and Huntington disease: Increasing evidence reveals that mTOR could be activated or inhibited depending on the pathologic status of the nervous system, e.g. brain tumors, tuberous sclerosis, cortical dysplasia and neurodegenerative diseases such as PD, Alzheimer's disease (AD), and Huntington's disease (HD) [28, 30].